Media headlines might suggest the pharmaceutical industry is bracing for impact due to pricing pressure, patent cliffs, executive orders, and tariff uncertainty. The IQVIA Institute for Human Data Science’s report, Global Medicine Use Trends 2026: Therapy Drivers, Spending Levels, and Policy Evolution, tells a different story. Grounded in data across more than a dozen markets and two decades of forecasting history, the report reveals that global growth continues—and, by historical standards, remains strong.

Last Year’s Forecast Held

The global medicine market is projected to grow at a 5% to 8% compound annual growth rate (CAGR) through 2030, reaching approximately $2.6 trillion. That range is unchanged from last year’s forecast.

It’s important to note that 5% to 8% CAGR is not a baseline expectation for this industry. Over the past decades, there have been extended periods in which growth stalled in the 2% to 5% range. In those periods, the outlook felt genuinely anemic. By contrast, the current range is historically elevated. Sustaining it through a period of significant policy uncertainty and a patent expiry wave expected to result in nearly $200 billion of brand losses — even larger than the one the industry navigated in 2011 and 2012 — is a meaningful finding.

The therapeutic areas driving most of the growth continue to be oncology, immunology, and endocrinology, particularly diabetes and obesity. Both oncology and immunology are expected to moderate somewhat later in the forecast period but remain strong contributors. Meanwhile, the GLP-1 story shows no signs of peaking.

The U.S. Market is Robust, but Context Is Everything

The United States remains the dominant force in global pharmaceutical spending. In absolute terms, U.S. five-year growth is expected to exceed the combined growth of the rest of the world — a figure that puts the market’s outsized role in sharp relief.

However, the number that matters most for commercial and strategic planning isn’t the list price figure; it’s the net price estimate. After accounting for rebates, discounts, and other concessions, which now offset nearly half of invoice value (about 46%), the IQVIA Institute forecasts U.S. net price growth at 4% to 7% CAGR through 2030.

That represents a step down from the past five years, during which the U.S. market grew at an exceptional 9.4% net CAGR, driven by strong performance across oncology, immunology, and obesity. A slowdown from that pace was always expected. The more important point is that 4% to 7% net growth in the world’s largest pharmaceutical market remains a robust environment by any historical comparison.

Policy Uncertainty: What’s Real vs. What’s Still Speculation

As this year’s report acknowledges, the policy landscape is genuinely complex, as the industry navigates Inflation Reduction Act (IRA) implementation, Most Favored Nation pricing frameworks, executive programs affecting drug pricing, and pharmacy benefit manager (PBM) reform. The list of active policy developments is long, and the media coverage can feel voluminous.

In assessing the global medicine market, the IQVIA Institute separated what has measurably arrived from what remains speculative. The first IRA drug price negotiations took effect in 2026, years after the legislation was first discussed. Many of the executive order programs are still working through legal challenges and implementation timelines. Historical precedent — including the fact that in its first five years, Medicare Part D’s costs came in roughly 50% lower than initial projections — serves as a reminder that modeled impacts in this space are frequently overstated.

The Institute’s U.S. forecast already embeds the known policy pressures, with sizing against the countervailing force of continued innovation, strong product performance, and expanding patient access. The net result is a market that is moderating from a historically high growth period, not one that is deteriorating.

Redrawing the Growth Map

Geographic nuances create one of the more compelling dimensions of this year’s report and were a focus of our recent webinar.

India’s medicine use is growing faster than traditional data collection had captured, driven in part by government-backed generic access programs that had previously been underrepresented in standard market audits. The volume growth is real, with significant public health implications.

The Gulf States, particularly Saudi Arabia and the United Arab Emirates (UAE), are emerging as genuine growth markets, supported by national health transformation programs and an expanding willingness to invest in access to innovative therapies. These are no longer markets on the periphery of the industry conversation.

At the same time, China’s story has pivoted in an interesting direction. Volume growth that once led the world is intentionally moderating through government pricing policy. And that’s happening as China becomes a meaningful source of global pharmaceutical innovation. This market accounted for nearly a third of large pharma in-licensing deals with upfronts of $50 million or more in 2024.

What the Data Means

The Global Medicine Use Trends 2026 report acknowledges that patent expiries, pricing pressure, and policy uncertainty are all realities in this environment. But the data also suggests that the macro case for continued investment in innovation remains intact. The companies well positioned to capitalize on that growth are building strategies around where the market is, not where the headlines suggest it could be going.

Dive deeper into the findings and analysis in the full report, Global Medicine Use Trends 2026: Therapy Drivers, Spending Levels, and Policy Evolution. For additional highlights, view the webinar recording.